COVID-19 diagnostics, a linchpin in controlling viral spread — what caused testing in the U.S. to fall so far behind and how can those missteps be prevented in the future? How do the diagnostics industry, and academic medicine, develop the tests that enable group activities including businesses sports, and community? What is the profile of diagnostic tests coming online in the coming months and into next year? What lessons can be learned to guide the global health community in future disease outbreaks? Given the biological complexity, required performance standards, and immense volume is a simple DTC assays possible on a greatly accelerated timeline. Moderator: Jeffrey Golden, MD, Chair, Department of Pathology, BH; Ramzi S. Cotran Professor of Pathology, HMS James Brink, MD, Chief, Department of Radiology, MGH; Juan M. Taveras Professor of Radiology, HMS John Iafrate, MD, PhD, Vice Chair, Academic Affairs, MGH; Professor, Pathology, HMS Celine Roger-Dalbert, VP Diagnostic Assays R&D – Integrated Diagnostic Solutions, BD Life Sciences Matt Sause, President and CEO, Roche Diagnostics Corporation
Course Includes
- 1 Lesson
